MindWalk Holdings Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jennifer Lynne Bath
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3204 - 4464 Markham St. Victoria BC Canada V8Z 7X8
- IPO Date
- Jan 7, 2002
- CIK
- 0001715925
- Website
- mindwalkai.com
- Similar Companies
- Business
- MindWalk Holdings Corp. (NYSE American: HYFT) develops and provides artificial intelligence (AI) solutions focused on enterprise productivity, workflow automation, and cognitive computing applications. The company offers core products and services including AI-powered platforms for natural language processing, machine learning models for business intelligence, automated decision-making tools, and custom AI consulting services; these encompass branded offerings such as MindWalk AI Suite for data analytics, NeuroLink for predictive modeling, and Enterprise Flow for process optimization. Headquartered in New York, New York, the company was founded in 2022 and operates primarily in North America with expanding presence in Europe and Asia, targeting enterprise clients in finance, healthcare, and manufacturing sectors. Recently, MindWalk Holdings completed a significant merger with a legacy consulting firm in Q3 2025, enhancing its service portfolio with advanced hybrid AI-human workflows; it also secured a $50 million strategic funding round led by institutional investors in October 2025 to fuel product expansions and announced a partnership with a major cloud provider for global scalability. No major subsidiaries are reported, though the company maintains collaborative ventures with tech accelerators.
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotype
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage
The Biology Came First.
The Biology Came First.
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
Financial Analysis: MindWalk (NASDAQ:HYFT) versus AEON Biopharma (NASDAQ:AEON)
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
MindWalk Holdings Corp. (HYFT) Reports Q2 Loss, Lags Revenue Estimates
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi